

- Name: Niels Reinmuth, MD PhD
- Current Position & Affiliation: Thoracic Oncology Department, Asklepios Lung Clinic
- Country: Germany

- Educational Background:

Dr Niels Reinmuth has been graduated from the University of Muenster, Germany, since 1997. In 1998 he completed his doctoral thesis on “A prospective study on prognostic factors in non-small cell lung cancer”.

- Professional Experience:

Between 1997-1999 he started his medical residency at the University Hospital Bergmannsheil, Bochum, Germany. Subsequently he performed a postdoctoral fellowship at the Department of Cancer Biology at the UT M.D.Anderson Cancer Center, Houston, Texas, until the end of 2001. In 2002, Niels Reinmuth continued his residency at the Department of Medicine/Haematology and Oncology, University of Muenster, Germany. In 2005 he moved to the Thoraxklinik Heidelberg, Department of Thoracic Oncology, University of Heidelberg, Germany. From 2012 until February 2016, Niels Reinmuth worked as Senior Physician at the Lung Clinic Grosshansdorf, Department of Thoracic Oncology, Grosshansdorf, Germany. Since February 2022 he has been appointed to an Associate Professor of Medicine.

Since March 2016, Niels Reinmuth has been leading the Thoracic Oncology Department at the Asklepios Lung Clinic in Munich-Gauting, Germany.

After passing his board certifications for “General Medicine”, “Haematology and General Oncology”, and “Pneumology” in 2007, 2008, and 2010, respectively, he was appointed Senior Physician. Moreover, he was awarded a post-doctoral lecturing qualification by the University of Heidelberg, Germany. Also, he completed specialty training in “Palliative Care Medicine”

Dr. Niels Reinmuth has been principal investigator and co- investigator for more than 200 clinical trials. He published more than 100 research articles and reviews in peer-reviewed journals. His main interests are targeted therapies in non-small-cell lung cancer and new approaches such as immunotherapies as well as translational research related to predictive markers.

- Professional Organizations:

Dr Reinmuth is member of the German Cancer Society, the German Society of Pulmonology, the International Association for the Study of Lung Cancer (IASLC), the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO).

- Main Scientific Publications:

Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study. Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, Majem M, Nackaerts K, Syrigos K, Hansen K, Schuette W, Cetnar J, Cappuzzo F, Okamoto I, Erman M, Langer SW, Kato T, Groen H, Sun Z, Luo Y, Tanwani P, Caffrey L, Komarnitsky P, Reinmuth N. *J Thorac Oncol*. 2021 Feb 16:S1556-0864(21)01709-3

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McClelland M, Mocchi S, Jassem J, Spigel DR. *N Engl J Med*. 2020 Oct 1;383(14):1328-1333

Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA, Westlin WF, Ellis LM. *Cancer Res*. 2003 May 1;63(9):2079-87.